OKYO Pharma Announces Participation in May 2024 Investor Conferences
OKYO Pharma Announces Participation in May 2024 Investor Conferences
London and New York, NY, May 8, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced upcoming presentations at two investor conferences in May 2024.
伦敦和纽约州纽约，2024年5月8日——OKYO Pharma Limited（纳斯达克股票代码：OKYO），一家处于临床阶段的生物制药公司，开发创新的眼部疗法，用于治疗价值数十亿美元的市场炎症性干眼病（DED）和前眼节疾病，包括神经病理性角膜疼痛（NCP），一种与疼痛有关但未获美国食品药品管理局批准的疗法的眼部疾病即将在2024年5月的两次投资者会议上发表演讲。
Conference: Aegis Capital Virtual Healthcare Conference
会议：Aegis Capital虚拟医疗会议
Date: Wednesday May 8, 2024, 11 AM EST
日期：美国东部标准时间 2024 年 5 月 8 日星期三上午 11 点
Location: Virtual
地点：虚拟
Presenter: Gary Jacob, PhD, Chief Executive Officer
主持人：加里·雅各布博士，首席执行官
Conference: Citizens JMP Securities Life Sciences Conference
会议：Citizens JMP 证券生命科学会议
Date: Monday May 13, 2024, 10:30 AM EST
日期：美国东部标准时间 2024 年 5 月 13 日星期一上午 10:30
Location: New York, NY
地点：纽约州纽约
Presenter: Gary Jacob, PhD, Chief Executive Officer
主持人：加里·雅各布博士，首席执行官
About OKYO
关于 OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
东洋制药有限公司（纳斯达克股票代码：OKYO）是一家临床阶段的生物制药公司，开发治疗DED和NCP的创新疗法，普通股在纳斯达克资本市场上市交易。OKYO 专注于发现和开发用于治疗炎症 DED 和眼痛的新分子。除了最近完成的二期 DED 试验外，OKYO 还计划启动 OK-101 的 2 期试验，以治疗患有这种虚弱性疾病的患者的 NCP。欲了解更多信息，请访问 www.okyopharma.com。
Enquiries:
查询：
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
| OKYO 制药有限公司 | Gary S. Jacob，首席执行官 | 917-497-7560 |
| 业务发展与投资者关系 | 保罗斯宾塞 | +44 (0) 20 7495 2379 |